Clinical Trial Update: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial to evaluate the safety and efficacy of fingolimod in Taiwanese adults with relapsing-remitting multiple sclerosis is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 4 | Status: RECRUITING